Literature DB >> 20862553

The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy.

Peter O Behan1, Abhijit Chaudhuri.   

Abstract

The literature for evidence of autoimmunity in multiple sclerosis (MS) is analysed critically. In contrast to the accepted theory, the human counterpart of the animal model experimental autoimmune demyelinating disease, experimental allergic encephalomyelitis (EAE), is not MS but a different demyelinating disorder, i.e. acute disseminated encephalomyelitis and acute haemorrhagic leucoencephalitis. Extrapolation of EAE research to MS has been guided largely by faith and a blind acceptance rather than sound, scientific rationale. No specific or sensitive immunological test exists that is diagnostic of MS despite the extensive application of modern technology. Immunosuppression has failed to have any consistent effect on prognosis or disease progression. The available data on MS immunotherapy are conflicting, at times contradictory and are based on findings in animals with EAE. They show predominantly a 30% effect in relapsing/remitting MS which suggests powerful placebo effect. Critical analysis of the epidemiological data shows no association with any specific autoimmune diseases, but does suggest that geographic factors and age at development posit an early onset possibly dependent on environmental influences. Certain neurological diseases are, however, found in association with MS, namely hypertrophic peripheral neuropathy, neurofibromatosis-1, cerebral glioma, glioblastoma multiforme and certain familial forms of narcolepsy. These share a common genetic influence possibly from genes on chromosome 17 affecting cell proliferation. A significant number of these disorders are of neural crest origin, the classical example being abnormalities of the Schwann cell. These and other data allow us to propose that MS is a developmental neural crest disorder, i.e. a cristopathy, implicating glial cell dysfunction with diffuse blood-brain barrier breakdown. The data on transcription factor SOX10 mutations in animals may explain these bizarre clinical associations with MS and the phenotypic variability of such alterations (Cossais et al. 2010). Research directed to the area of neural crest associations is likely to be rewarding.

Entities:  

Mesh:

Year:  2010        PMID: 20862553     DOI: 10.1007/s10787-010-0054-4

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   5.093


  231 in total

Review 1.  Interferon in relapsing-remitting multiple sclerosis.

Authors:  G P Rice; B Incorvaia; L Munari; G Ebers; C Polman; R D'Amico; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2001

2.  Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis.

Authors:  M S Freedman; K L Muth; J L Trotter; C N Yoshizawa; J P Antel
Journal:  Neurology       Date:  1992-08       Impact factor: 9.910

3.  X-linked Charcot-Marie-Tooth disease and progressive-relapsing central demyelinating disease.

Authors:  G Isoardo; N Di Vito; M Nobile; G Benetton; F Fassio
Journal:  Neurology       Date:  2005-11-22       Impact factor: 9.910

4.  Demyelinating neuropathy in a patient with multiple sclerosis and genotypical HMSN-1.

Authors:  M Almsaddi; T E Bertorini; W K Seltzer
Journal:  Neuromuscul Disord       Date:  1998-04       Impact factor: 4.296

5.  Induced localization of allergic adrenalitis and encephalomyelitis at sites of thermal injury.

Authors:  S Levine; E M Hoenig
Journal:  J Immunol       Date:  1968-06       Impact factor: 5.422

6.  Mitochondrial encephalomyopathy: comparison of conventional MR imaging with diffusion-weighted and diffusion tensor imaging: case report.

Authors:  Charles B Majoie; Erik M Akkerman; Christian Blank; Peter G Barth; Bwee Tien Poll-The; G J den Heeten
Journal:  AJNR Am J Neuroradiol       Date:  2002-05       Impact factor: 3.825

7.  Long-term changes in the spinal cords of patients with old poliomyelitis. Signs of continuous disease activity.

Authors:  G H Pezeshkpour; M C Dalakas
Journal:  Arch Neurol       Date:  1988-05

8.  Chronic granulomatous anterior uveitis associated with multiple sclerosis.

Authors:  M A Acar; M K Birch; R Abbott; A R Rosenthal
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-03       Impact factor: 3.117

9.  Malignant diseases among patients with multiple sclerosis.

Authors:  J Palo; J Duchesne; J Wikström
Journal:  J Neurol       Date:  1977-10-07       Impact factor: 4.849

Review 10.  A mitochondrial component of neurodegeneration in multiple sclerosis.

Authors:  Bernadette Kalman; Thomas P Leist
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 4.103

View more
  6 in total

1.  Quo vadis multiple sclerosis?

Authors:  Israel Steiner; Ronit Mosberg-Galili
Journal:  Inflammopharmacology       Date:  2010-11-03       Impact factor: 4.473

Review 2.  The conundrum of iron in multiple sclerosis--time for an individualised approach.

Authors:  Susan J van Rensburg; Maritha J Kotze; Ronald van Toorn
Journal:  Metab Brain Dis       Date:  2012-03-17       Impact factor: 3.584

3.  Paradigms in multiple sclerosis: time for a change, time for a unifying concept.

Authors:  Bernd Krone; John M Grange
Journal:  Inflammopharmacology       Date:  2011-05-06       Impact factor: 4.473

4.  Neural crest cell genes and the domestication syndrome: A comparative analysis of selection.

Authors:  Andrew O Rubio; Kyle Summers
Journal:  PLoS One       Date:  2022-02-11       Impact factor: 3.240

5.  Is a hypothetical melanoma-like neuromelanin the underlying factor essential for the aetiopathogenesis and clinical manifestations of multiple sclerosis?

Authors:  Bernd Krone; John M Grange
Journal:  BMC Neurol       Date:  2013-07-18       Impact factor: 2.474

Review 6.  Neural crest: The fourth germ layer.

Authors:  K Shyamala; Sarita Yanduri; H C Girish; Sanjay Murgod
Journal:  J Oral Maxillofac Pathol       Date:  2015 May-Aug
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.